Literature DB >> 16794637

Drug interactions in cancer therapy.

Charity D Scripture1, William D Figg.   

Abstract

Drug interactions in oncology are of particular importance owing to the narrow therapeutic index and the inherent toxicity of anticancer agents. Interactions with other medications can cause small changes in the pharmacokinetics or pharmacodynamics of a chemotherapy agent that could significantly alter its efficacy or toxicity. Improvements in in vitro methods and early clinical testing have made the prediction of potentially clinically significant drug interactions possible. We outline the types of drug interaction that occur in oncology, the mechanisms that underlie these interactions and describe select examples.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16794637     DOI: 10.1038/nrc1887

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  80 in total

Review 1.  CHIP and gp78-mediated ubiquitination of CYP3A4: Implications for the pharmacology of anticancer agents.

Authors:  Cody J Peer; Tristan M Sissung; William D Figg
Journal:  Cancer Biol Ther       Date:  2011-03-15       Impact factor: 4.742

2.  Prevalence of potential drug-drug interactions in bone marrow transplant patients.

Authors:  Rosimeire Barbosa Fonseca Guastaldi; Adriano Max Moreira Reis; Albert Figueras; Silvia Regina Secoli
Journal:  Int J Clin Pharm       Date:  2011-10-13

Review 3.  The secret ally: immunostimulation by anticancer drugs.

Authors:  Lorenzo Galluzzi; Laura Senovilla; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Rev Drug Discov       Date:  2012-02-03       Impact factor: 84.694

4.  Smart Nanoscale Drug Delivery Platforms from Stimuli-Responsive Polymers and Liposomes.

Authors:  Sang-Min Lee; SonBinh T Nguyen
Journal:  Macromolecules       Date:  2013-11-27       Impact factor: 5.985

Review 5.  Introducing the Big Knowledge to Use (BK2U) challenge.

Authors:  Yehoshua Perl; James Geller; Michael Halper; Christopher Ochs; Ling Zheng; Joan Kapusnik-Uner
Journal:  Ann N Y Acad Sci       Date:  2016-10-17       Impact factor: 5.691

6.  PharmGKB: an integrated resource of pharmacogenomic data and knowledge.

Authors:  Li Gong; Ryan P Owen; Winston Gor; Russ B Altman; Teri E Klein
Journal:  Curr Protoc Bioinformatics       Date:  2008-09

7.  Prevalence of drug-drug interactions in sarcoma patients: key role of the pharmacist integration for toxicity risk management.

Authors:  Audrey Bellesoeur; Ithar Gataa; Pascaline Boudou-Rouquette; Audrey Thomas-Schoemann; Anne Jouinot; Sarah El Mershati; Anne-Catherine Piketty; Camille Tlemsani; David Balakirouchenane; Anthia Monribot; Michel Vidal; Rui Batista; Sixtine de Percin; Clémentine Villeminey; Jérôme Alexandre; François Goldwasser; Benoit Blanchet
Journal:  Cancer Chemother Pharmacol       Date:  2021-07-24       Impact factor: 3.333

8.  Reduced exposure of imatinib after coadministration with acetaminophen in mice.

Authors:  Inthisham Nassar; Thanikachalam Pasupati; John Paul Judson; Ignacio Segarra
Journal:  Indian J Pharmacol       Date:  2009-08       Impact factor: 1.200

9.  Histopathology and biochemistry analysis of the interaction between sunitinib and paracetamol in mice.

Authors:  Adeline Yl Lim; Ignacio Segarra; Srikumar Chakravarthi; Sufyan Akram; John P Judson
Journal:  BMC Pharmacol       Date:  2010-10-15

10.  Drug-virus interaction: effect of administration of recombinant adenoviruses on the pharmacokinetics of docetaxel in a rat model.

Authors:  P Wonganan; W C Zamboni; S Strychor; J D Dekker; M A Croyle
Journal:  Cancer Gene Ther       Date:  2008-12-26       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.